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Available online 25 May 2016Evaluation of speciﬁc antibody (Ab) response to polysaccharide antigens is essential for diagnosis of primary
immunodeﬁciencies. We assessed the speciﬁc Ab responses to the pneumococcal-polysaccharide (PPV) and to
Salmonella typhi-polysaccharide (TyphimVi) vaccines in a prospective study (EMPATHY) in patients with com-
mon variable immunodeﬁciency (CVID-Group, n=22), hypogammaglobulinemia (HYPOG-Group; n=27) and
healthy controls (HC-Group; n = 16). Speciﬁc Ab concentrations in response to PPV and to TyphimVi vaccines
were measured by ELISA (The Binding Site, UK), deﬁning 3-fold increase as normal response (Ratio:3×). The
RatioTyphimVi:3× was signiﬁcantly greater in HC than in CVID-Group (p b 0.0001), but not than HYPOG-
Group (p = 0.138). However, the RatioPPV:3× showed no signiﬁcant differences among the three groups. By
ROC analysis, TyphimVi better differentiated HC from CVID (AUC:0.893, IC95%: 0.791–0.996, p b 0.0001) than
PPV. Our results suggest that the use of speciﬁc Ab response to TyphimVi could represent a complementary
assay for the diagnosis of anti-polysaccharide Ab production deﬁciency in patients with CVID.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Evaluation of speciﬁc antibody response to polysaccharide antigens
is essential for diagnosis and management decisions of primary immu-
nodeﬁciency diseases (PIDD) [1,2,3]. Indeed, deﬁciency of speciﬁc poly-
saccharide antibody responses renders individuals susceptible tothe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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teria, and an adequate diagnosis helps to deﬁne those who may beneﬁt
from immunoglobulin replacement therapy [4]. Measurement of the
antibody response to pure nonconjugated Pneumovax 23® (PPV), a
23-valent pneumococcal polysaccharide vaccine, is the gold standard
test to identify deﬁciencies in anti-polysaccharide antibody production.
A vaccine response is considered adequate when post-vaccination
speciﬁc antibody concentration is N1.3 mg/L per serotype for serotype
analysis, N50 mg/L if using a pneumococcal IgG ELISA [2,4–7] and
more than a three to four-fold increase in anti-PPV antibody titers
above the pre-vaccination concentration [8,9]. Measurement of fold-
increase should always be interpreted in combination with the post-
vaccination antibody concentration. However, the interpretation of
pneumococcal antibody production using PPV can be challenging for
the following reasons: the recent introduction of polysaccharide-
protein conjugated vaccine in the vaccination schedule which could
mask a pure PPV driven IgG2 polysaccharide response; cross-reacting
and different immunogenicities among antibodies towards different se-
rotypes, high PPV pre-immunization levels in general population, high
prevalent natural infection by S. Pneumoniae [10,11]; and other issues
related to inter-individual variability. It would therefore be of interest
if an additional assay were available to assess the response to another
polysaccharide antigen/vaccine in individuals with heterogeneous
genetic disorders such as common variable immunodeﬁciency (CVID).
Recently, a novel vaccine response assay has become commercially
available. The Salmonella typhi Vi IgG ELISA measures the response to
the Typhim Vi polysaccharide vaccine which was licensed in 1988 for
use in adults and children N18months of age [12,13]. Themain purpose
of the current studywas to analyse the speciﬁc production of antibodies
raised in response to Typhim Vi using the Salmonella typhi Vi IgG ELISA
Assay and compare to the production of antibodies raised to PPV and to
evaluate its use as a complementary diagnostic tool for interpreting
quantiﬁcation of anti-polysaccharide responses in PIDD.
2. Patients and methods
2.1. Subjects
A prospective multicenter study (EMPATHY; including 18 Spanish
centres)was conducted in 49 adult patients (aged 20 to 65 yrs) that pre-
sented with hypogammaglobulinemia, deﬁned as serum IgG plus IgA
≤600 mg/dL, and were subsequently referred to the participating cen-
ters for evaluation of suspected immunodeﬁciency. All patients
underwent clinical and immunological examination andwere classiﬁed
as either: Common Variable Immunodeﬁciency (CVID-Group; n= 22),
according to the European Society of Immunodeﬁciencies (ESID) and
the Pan American Group for Immune deﬁciency (PAGID) criteria [14],
or Hypogammaglobulinemia (HYPOG-Group; n= 27). None of the pa-
tients had previously received intravenous gammaglobulin therapy.We
sought to analyse the speciﬁc antibody response to puriﬁed Typhim Vi
polysaccharide antigen from S. typhi in comparison to pneumococcal
antigens in PPV for PIDD diagnosis. Sixteen asymptomatic volunteers
of similar age and gender to the patient group that underwent Typhim
Vi and PPV vaccination were selected to act as the healthy control
group (HC-Group). The study was approved by the Ethical Committees
of the participating centers and by the Agencia Española de
Medicamentos y Productos Sanitarios (Spanish Agency of Medicines
and Medical Devices).
After obtaining full informed and written consent, in all study sub-
jects a morning blood sample was drawn for baseline pre-vaccination
speciﬁc Ab levels, full blood count, total immunoglobulins (IgG, IgA
and IgM) and IgG subclasses levels, baseline pneumococcal and
S. typhi speciﬁc IgG antibodies. At the time of this study, vaccination
with PPV (Pneumo23™, Sanoﬁ Pasteur MSD Limited, Maidenhead,
Berks, UK) and Salmonella Typhi vaccines (available in Spain as Typhim
Vi™, Sanoﬁ Pasteur MSD), were administered. After an interval of28 days (±3 days) post PPV and Typhim Vi vaccination, blood was
drawn from all subjects. Pre- and post-immunization serum samples
were separated by centrifugation and then stored in aliquots at
−40 °C until simultaneous performance of speciﬁc antibody tests.
2.2. Antibody testing
Total immunoglobulins were measured using commercial kits on
an Immage (Beckman Coulter) nephelometer. IgG subclasses were
measured using a Turbidimetry method (The Binding Site Group Ltd.,
Birmingham, UK) as previously described [15].
Speciﬁc antibodies to PPV and to Typhim Vi vaccinesweremeasured
using commercially available ELISA kits (VaccZyme™ Anti-PCP IgG EIA
and VaccZyme™ Anti-S. typhi Vi human IgG EIA from The Binding Site
Group Ltd., Birmingham, UK). Serum samples pre and post vaccinations
for all patients and controls were tested in the same centralized labora-
tory at Hospital General Universitario Gregorio Marañón, which has
accredited PVP ELISA test by the UNE-EN ISO 15189 quality standards
in Spain. Sampleswere run in duplicate followingmanufacturer instruc-
tions. The results of speciﬁc antibody levels to Typhim Vi are expressed
as U/mL (range, 7.4–600 U/mL). PPV antibody levels are given as mg/dL
(range, 0.33–27 mg/L). The values of these responses are given as the
ratio between pre- and post- immunization antibody levels. We used
a three-fold increase between titres pre and post vaccination to deﬁne
a normal antibody response according to prior studies [8,9].
2.3. Statistical evaluation
Descriptive data are presented as mean ± standard deviation (SD)
or median values. Differences in antibody responses between groups
were evaluated by Mann-Whitney U test. The Wilcoxon matched-
pairs signed rank-sum test was used to assess the statistical signiﬁcance
between pre- and post-immunization antibody levels. Receiver operat-
ing characteristic (ROC) curves were used to select the optimal cut-off
values of signiﬁcant variables for diagnosis of CVID based on the opti-
mum sensitivity and speciﬁcity. Data were analyzed with SPSS software
(Chicago, Illinois). The criterion for signiﬁcance was set at P b 0.05.
3. Results
3.1. Epidemiological characteristics of the study subjects
A total of 65 subjects were studied (Table 1): All three groups were
aged matched and were not signiﬁcantly different. Serum IgG, IgM
and IgA were signiﬁcantly lower for both the hypogammaglobulinemia
and CVID groups compared to the HC group. In addition, IgG was also
signiﬁcantly lower between both hypogammaglobulinemia and CVID
groups.
Serum IgG subclasses were signiﬁcantly different between the
groups (CVID vs HYPO vs HC) (Table 1). Pneumococcal and Typhim Vi
vaccines were well tolerated and there was no moderate or severe ad-
verse event in healthy control or patients groups. Pain at the injection
site was the only adverse effect reported (n= 7) for both vaccines.
3.2. Polysaccharide antibody responses to PPV and Typhim Vi
The median pre-vaccination concentrations, post vaccination con-
centrations and fold increases in concentrations for both Typhi Vi and
PPV antibodies are shown in Table 2 and Fig. 1A. Shapiro–Wilk test for
Gaussian distribution demonstrated that Typhi Vi IgG and PCP IgG
concentrations were not normally distributed (p ≤ 0.004). The pre
vaccination concentrations were not signiﬁcantly different for Typhi Vi
antibodies but were signiﬁcantly different for the PCP IgG antibodies
between the three groups. Post vaccination, signiﬁcance was achieved
between the PCP IgG concentrations from the three groups. The same
was observed for Typhi Vi concentrations with the exception that the
Table 1
Epidemiological and clinical characteristics of patients included in the study.
CVID HYPOG pa HC pb pb
Number of patientsa 22 27 – 16 – –
Gender F/Ma 15/7 16/11 NS 9/6 NS NS
Age, yearsb 45.8 ± 15.5 41.2 ± 18.9 NS 39.8 ± 12.8 NS NS
Serum IgG 360.8 ± 161.5 524.1 ± 180.5 0.01 1055.8 ± 242.5 b0.0001 b0.0001
Serum IgA 50.7 ± 39.5 90.7 ± 72.3 0.07 161.4 ± 34.6 b0.0001 0.01
Serum IgM 55.1 ± 31.2 47.3 ± 25.4 NS 164.9 ± 56.7 b0.0001 b0.0001
Serum IgG1 279.4 ± 134.4 376.4 ± 100.3 0.02 548.4 ± 102.3 0.003 0.003
Serum IgG2 92.0 ± 61.6 142.4 ± 108.7 0.08 340.2 ± 174.7 0.005 0.006
a Comparison of CVID vs. HYPOG, MW test used for assessment of signiﬁcance.
b Comparison of CVID vs. HC and HYPOG vs. HC, MW test used for assessment of signiﬁcance.
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and hypogammaglobulinemia group were not signiﬁcantly different.
At baseline levels, 6/22 CVID patients (27%), 15/27 patients (55%)
in the HYPOG-Group and 15/16 (94%) subjects in the HC-Group had
anti-PPV titres (N50 mg/L).
Post vaccination, 11/22 CVID patients (50%), 25/27 patients (93%) in
the HYPOG-Group and 16/16 (100%) individuals in the HC-Group had
anti-PPV titres (N50 mg/L). Using the minimum post vaccination con-
centration for Typhi Vi in HC (32 U/mL) as a cut off, 9/22 (41%) and
17/27 (63%) of CVID and hypogammaglobulinemia patients achieved a
post vaccination concentration N 32 U/mL.
Fig. 1A shows that the Typhim Vi Ratio was signiﬁcantly higher in
HC-Group compared to CVID group (p b 0.0001), but not with respect
to HYPOG group (p=0.138). By contrast, the Ratio PPV was not signif-
icantly different between the 3 groups (HC vs CVID (p=0.693) and HC
vs HYPOG (p=0.052) (Fig. 1B). All subjects in the HC-Group were able
to mount a ≥ 3-fold antibody response on Typhim Vi immunization ver-
sus only 40.3%of CVID-Group subjects (p=0.003) and 64.4% ofHYPOG-
Group patients (p = 0.006), respectively. Using ROC analysis, the
area under the curve (AUC) was higher using Typhim Vi vaccination
[AUC Ratio Typhim Vi ≥3×: 0.893 (95%CI: 0.791–0.996, p b 0.0001)]
(Fig. 2A) compared with anti-PPV vaccination [AUC Ratio PPV ≥3×:
0.538 (95%CI: 0.354–0.722), p=0.690)] (Fig. 2A and B). The analysis re-
vealed that Ratio Typhi was the most signiﬁcant parameter that differ-
entiated the Ab responses to PS vaccines between the CVID group and
HC group. The statistically chosen cutoff value for the ratio of Typhim
Vi in ourHCpopulationwas 10 fold based in sensitivity for CVID diagno-
sis of 90.9%, and speciﬁcity of 62.5%, respectively. Using a cutoff of 10
fold increase, a greater number of subjects with b10 fold increase in
Typhim Vi Ratio antibody response belonged to the CVID-Group
(90.9% in the CVID-Group versus 51.9% in the HYPOG-Group versus
31.3% in the HC-Group, respectively) (p= 0.0002).
Discrepancies between the results of measurement of antibodies to
polysaccharide antigens were observed mainly in the CVID group
(59.7% no response to Vi-antigen vs. 72.2% no response to PPV-
antigens). The global discrepancy between both methods was 34%
(21/61), which could be inﬂuenced by baseline levels of anti-PPVTable 2
Responses to Typhim Vi and Pneumovax vaccination in healthy controls, hypogammaglobinem
CVID HYPOG
Typhi Vi
Pre-vaccination concentration (U/mL) 7.4 (7.4–69.8) 7.4 (7.4–75
Post-vaccination concentration (U/mL) 21 (7.4–277) 63.3 (7.4–60
Fold increase 1.8 (1 to 37.4) 8.6 (1 to 81
PPV
Pre-vaccination concentration (mg/dL) 2.4 (0.33–27) 7.4 (0.6–27
Post-vaccination concentration (mg/dL) 5.8 (0.33–27) 22.4 (1.4–27
Fold increase 1.3 (0.33–73) 2.1 (1–13.5
All values represent median (range min-max).
a Comparison of CVID vs. HC and HYPOG vs. HC, MW test used for assessment of signiﬁcanc
b Comparison of CVID vs. HYPOG, MW test used for assessment of signiﬁcance.antibodies (29.5% for global mean ≥ 0.08 g/L and 47.1% for controls
mean ≥ 0.2 g/L).
3.3. Stratiﬁcation of CVID patients
Using the response to Typhim Vi, two CVID patients had a ≥ 10 fold
response (median value 24.8; range 12.2 to 37.5) and 20 had a ≤ 10
fold increase (median value 2.4; range 1 to 7.2,).
4. Discussion
Prior consensus on the use and interpretation of diagnostic vaccina-
tion in PIDD suggested the potential of Typhim Vi vaccine as an
alternative diagnostic tool for assessing antibody production against
polysaccharide antigen, although lack of available clinical data limited
its routine recommendation [4,16]. Our results in this study indicate
that the evaluation of the speciﬁc antibody response to Typhim Vi vac-
cine adds clinical value to the diagnosis of anti-polysaccharide antibody
production deﬁciency in patients with CVID.
The CVID-Group elicited a similar lack of response to both TyphimVi
and PCP immunization (ratios of 1.8 and 1.3, respectively), which sug-
gests the possibility to use Typhim Vi immunization in conjunction
with classical Pneumo23 for diagnostic purposes and for clinical moni-
toring. Moreover, our results point to better power for discriminating
between groups for anti-Typhim Vi antibodies production with respect
to the gold-standard of PPV antibody production. Indeed, using statisti-
cal ROC analysis for our population to deﬁne the most optimal cutoff
level for ratio Typhim Vi and PPV, only the response to Typhim Vi was
signiﬁcant. For Typhim Vi response a 10 fold increase was highly
signiﬁcant, with 90.9% sensitivity and 62.5% speciﬁcity, respectively,
for CVID diagnosis.
In all three groups, relative to the post vaccination concentration,
the pre vaccination concentration of pneumococcal antibodies was
relatively high which resulted in lower median fold increases in
concentration. The pre vaccination concentrations of Typhi Vi were
not signiﬁcantly different between the three groups and the median
concentration was very low (≤9 U/mL). Thus, this could aid in theic and CVID patients.
p* HC pa pa
.2) NS 8.6 (7.4–31.8) NS NS
0) 0.006 171 (32–600) b0.0001 NS
.1) 0.02 12.3 (3.4–76.9) b0.0001 NS
) 0.02 20.3 (2.9–27) 0.0003 0.007
) 0.006 27 (24.8–27) b0.0001 0.002
) NS 1.3 (1–8.6) NS NS
e.
Fig. 1. Comparison between groups by increase in polysaccharide antibody responses. Fig. 1A: Box plots showing that the Ratio Typhim Viwas signiﬁcantly higher in HC-group compared
to CVID-group (p b 0.0001), but notwith respect toHYPOG-group (p=0.138). In contrast, the Ratio PPV did not showsigniﬁcant differences between the 3 groups (HCvs CVID, p=0.693;
and HC vs HYPOG, p=0.052) (Fig. 1B). Each box plot represents themedian (thick band) and the 25th and 75th centiles. The error bars represent the smallest and largest values that are
not outliers.
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diagnoses of hypogammaglobulinemia and CVID which was not possi-
ble with assessment of the antibody response to PPV.
Ferry and colleagues have proposed the use of a Typhim Vi as a suit-
able polysaccharide immunogen for PIDD investigation [8]. The pre- and
post-vaccination fold increase was studied in a healthy population. The
median value of for pre-vaccination titres was 3.9 AU/mL and for post-
vaccination 39.2 AU/mL, indicating a 10 fold increase in titres. In agree-
ment with the present study, we calculated that 10 fold increase in the
HC groupwould give the best differentiation of a response between theFig. 2. Receiver operating characteristic (ROC) curve analyses using Typhim Vi and PPV
ratio as predictor of diagnosis of CVID. The curves show the trade-off between
sensitivity and speciﬁcity. An increase in sensitivity will be accompanied by a decrease
in speciﬁcity. The accuracy of the prediction increases as the curve approaches the left-
hand and top portions of the ROC space. The area under the curve (AUC) is the
percentage of randomly drawn pairs for which the prediction is true. As observed, the
ratio Typhim Vi better deﬁned CVID patients (p b 0.0001).HC group and CVID group [8]. Perhaps an intriguing observation from
this studywas the possible identiﬁcation of two CVID groups of patients
stratiﬁed according to their response to Typhim Vi. Unfortunately, the
numbers of patients in the group that possess a ≥ 10 fold increase to vac-
cinationwere too small to examine further, but it is tempting to suggest
that this group might have a more proﬁcient immunological response
and thus a lower predisposition to infection [17,18]. This is strength-
ened by the observation that the two patients with ≥10 fold increase
to Typhim Vi had a lower number of respiratory infections and no
CVID linked inﬂammatory conditions.
With this in mind, Cavaliere et al. have recently demonstrated that
PPV IgA and IgM vaccine response subgroups exist in CVID patients
and that this stratiﬁcation served as an indication to risk of pneumonia
and bronchiectasis [19]. A larger study is required to understand the sig-
niﬁcance of this observation and to see whether there is any overlap
with pneumococcal IgA and IgM response in the same cohort.
Variable pneumococcal polysaccharide vaccine responses have been
reported in patients with CVID, with some patients showing some de-
gree of responsiveness [20,21]. The high baseline level of pneumococcal
antibodies from endemic infection ensures that interpretation of re-
sponse between HC and CVID groups remains challenging. Discrepan-
cies in antibody production between anti-Typhim Vi and anti-PPV
tests were observed in this study.
Pneumovax 23 polysaccharide vaccine continues to be widely used
in routine clinical immunology practice; even though systematic vacci-
nation with the protein conjugated Prevenar vaccine may limit its use
for assessing speciﬁc polysaccharide responses. Use of the S. typhi poly-
saccharide vaccine may provide further immunological insight to un-
ravel subtle defects in the response to polysaccharide antigens.
In conclusion, this study strongly supports the diagnostic utility of
S. typhi IgG ELISA for the diagnosis of the heterogeneous population of
CVID patients. Further studies with larger number of subjects should
be performed to conﬁrm the utility of Typhim Vi to assess speciﬁc anti-
body responses in suspected antibody primary immunodeﬁciencies.
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